CY1115504T1 - Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη - Google Patents
Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινηInfo
- Publication number
- CY1115504T1 CY1115504T1 CY20141100686T CY141100686T CY1115504T1 CY 1115504 T1 CY1115504 T1 CY 1115504T1 CY 20141100686 T CY20141100686 T CY 20141100686T CY 141100686 T CY141100686 T CY 141100686T CY 1115504 T1 CY1115504 T1 CY 1115504T1
- Authority
- CY
- Cyprus
- Prior art keywords
- complexes
- platinum
- cisplatin
- phosphoplatin
- fas
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- BHKICZDKIIDMNR-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound N.N.[Pt+4].[O-]C(=O)C1(C([O-])=O)CCC1 BHKICZDKIIDMNR-UHFFFAOYSA-L 0.000 title 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 229960004316 cisplatin Drugs 0.000 abstract 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 3
- KTCQVFPGCRGZPS-UHFFFAOYSA-N P(=O)(=O)[Pt] Chemical compound P(=O)(=O)[Pt] KTCQVFPGCRGZPS-UHFFFAOYSA-N 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229960004562 carboplatin Drugs 0.000 abstract 2
- 190000008236 carboplatin Chemical compound 0.000 abstract 2
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- PVGAVTXIFQJKJI-UHFFFAOYSA-H platinum(2+);diphosphate Chemical compound [Pt+2].[Pt+2].[Pt+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O PVGAVTXIFQJKJI-UHFFFAOYSA-H 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει φωσφαπλατίνες, σταθερά απομονωμένα μονομερή φωσφατο σύμπλοκα λευκόχρυσος (II) και (IV) και μεθόδους για τη χρήση αυτών για τη θεραπεία καρκίνων, συμπεριλαμβανομένων των καρκίνων που είναι ανθεκτικοί στη σισπλατίνη και την καρβοπλατίνη. Αντίθετα με τη σισπλατίνη, αυτά τα σύμπλοκα δεν υπόκεινται εύκολα σε υδρόλυση και είναι αρκετά διαλυτά και σταθερά σε υδατικά διαλύματα. Επιπλέον, αυτά τα σύμπλοκα - αντίθετα με τη σισπλατίνη, καρβοπλατίνη, και σχετικούς αντικαρκινικούς παράγοντες με βάση το λευκόχρυσο δεν συνδέονται με το DΝΑ. Αντιθέτως, τα δεδομένα υποδεικνύουν ότι οι φωσφαπλατίνες προκαλούν υπερέκφραση των παραγόντων μεταγραφής fas και fas-σχετικών και μερικά γονίδια προαπόπτωσης όπως τα Bak και Βax. Εν τούτοις, τα σύμπλοκα εμφανίζουν πολύ μεγάλη κυτταροοτοξικότητα έναντι των καρκινικών κυττάρων. Έτσι, η παρούσα εφεύρεση παρέχει καινοτόμους αντικαρκινικούς παράγοντες λευκόχρυσου οι οποίοι έχουν διαφορετικό μοριακό στόχο απ' ότι οι παράγοντες της γνωστής στάθμης της τεχνικής.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| EP08797320.2A EP2173337B1 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115504T1 true CY1115504T1 (el) | 2017-01-04 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100686T CY1115504T1 (el) | 2007-08-06 | 2014-08-27 | Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (el) |
| EP (2) | EP2668949A1 (el) |
| JP (2) | JP5385274B2 (el) |
| CN (1) | CN101801369B (el) |
| CY (1) | CY1115504T1 (el) |
| DK (1) | DK2173337T3 (el) |
| ES (1) | ES2495743T3 (el) |
| HK (1) | HK1143551A1 (el) |
| HR (1) | HRP20140808T1 (el) |
| PL (1) | PL2173337T3 (el) |
| PT (1) | PT2173337E (el) |
| SI (1) | SI2173337T1 (el) |
| WO (2) | WO2009021081A2 (el) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668949A1 (en) * | 2007-08-06 | 2013-12-04 | Ohio University | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
| AP3480A (en) * | 2010-06-04 | 2015-12-31 | Univ Ohio | Phosphaplatins and their use for treatment of cancers |
| JP2014502634A (ja) | 2011-01-12 | 2014-02-03 | オハイオ ユニバーシティー | 抗血管新生、抗転移、及びアポトーシス促進の特性を有するホスファプラチン並びにそれらの使用 |
| US9284440B2 (en) | 2011-07-08 | 2016-03-15 | Dow Global Technologies Llc | Polyethylene blend composition suitable for blown film, method of producing the same, and films made therefrom |
| CA2851254A1 (en) | 2011-10-05 | 2013-04-11 | Shadi MOGHADDAS | Efficient processes for large scale preparation of phophaplatins antitumor agents |
| JP6027619B2 (ja) | 2011-10-05 | 2016-11-16 | ラシンドラ・エヌ・ボーズ | ホスファプラチン系抗腫瘍剤の大規模調製のための効率的プロセス |
| CN110269940A (zh) | 2011-10-20 | 2019-09-24 | 奈瑞姆生物技术公司 | 用于治疗癌症的治疗组合 |
| IN2014KN02722A (el) | 2012-05-24 | 2015-05-08 | Phosplatin Therapeutics Llc | |
| US9333211B2 (en) * | 2013-02-22 | 2016-05-10 | University Of Houston System | Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof |
| EP3107534A4 (en) * | 2014-02-19 | 2017-09-06 | The University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| MX370673B (es) | 2014-06-11 | 2019-12-19 | Univ Texas | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. |
| EP3397642A1 (en) | 2015-12-30 | 2018-11-07 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| EP3565561A4 (en) | 2017-01-06 | 2020-08-26 | Phosplatin Therapeutics LLC | PHOSPHAPLATIN COMPOUNDS AS THERAPEUTICS FOR THE TREATMENT OF BONE / BLOOD CANCER |
| AU2018327339B2 (en) * | 2017-09-08 | 2023-10-12 | Promontory Therapeutics Inc. | Phosphaplatin compounds as immuno-modulatory agents and therapeutic uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| US4291027A (en) | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Leslie S. Hollis | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| EP1644388A2 (en) | 2003-06-27 | 2006-04-12 | ODANI, Akira | Bisphosphonate complexes |
| US20110034714A1 (en) * | 2007-07-06 | 2011-02-10 | Hisao Ekimoto | Metal complex compound, cancer therapeutic agent composition containing the metal complex compound as an active ingredient, and intermediate for the metal complex compound |
| EP2668949A1 (en) * | 2007-08-06 | 2013-12-04 | Ohio University | Phosphaplatins and their use in the treatment of cancers resistant to cisplatin and carboplatin |
-
2008
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Application Discontinuation
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en active Application Filing
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
- 2010-10-29 HK HK10110187.0A patent/HK1143551A1/xx unknown
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 HR HRP20140808AT patent/HRP20140808T1/hr unknown
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2173337E (pt) | 2014-09-03 |
| HRP20140808T1 (hr) | 2014-10-24 |
| US20090042838A1 (en) | 2009-02-12 |
| ES2495743T3 (es) | 2014-09-17 |
| US8445710B2 (en) | 2013-05-21 |
| EP2668949A1 (en) | 2013-12-04 |
| PL2173337T3 (pl) | 2014-11-28 |
| WO2009021081A3 (en) | 2009-05-07 |
| WO2009021081A2 (en) | 2009-02-12 |
| US8653132B2 (en) | 2014-02-18 |
| EP2173337A2 (en) | 2010-04-14 |
| EP2173337B1 (en) | 2014-07-30 |
| EP2173337A4 (en) | 2010-10-27 |
| JP2010535803A (ja) | 2010-11-25 |
| DK2173337T3 (da) | 2014-09-15 |
| HK1143551A1 (en) | 2011-01-07 |
| JP5647300B2 (ja) | 2014-12-24 |
| CN101801369A (zh) | 2010-08-11 |
| WO2009021082A2 (en) | 2009-02-12 |
| US20100233293A1 (en) | 2010-09-16 |
| JP5385274B2 (ja) | 2014-01-08 |
| US8034964B2 (en) | 2011-10-11 |
| CN101801369B (zh) | 2012-09-19 |
| US7700649B2 (en) | 2010-04-20 |
| US20130237503A1 (en) | 2013-09-12 |
| WO2009021082A3 (en) | 2009-04-23 |
| SI2173337T1 (sl) | 2014-10-30 |
| JP2013227218A (ja) | 2013-11-07 |
| US20110313182A1 (en) | 2011-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115504T1 (el) | Φωσφαπλαντινες και η χρηση τους στη θεραπεια καρκινων ανθεκτικων στη σισπλαντινη και τη καρβοπλατινη | |
| Vojtek et al. | Anticancer activity of palladium-based complexes against triple-negative breast cancer | |
| Wani et al. | Recent advances in iron complexes as potential anticancer agents | |
| Xiao et al. | A dual-targeting hybrid platinum (IV) prodrug for enhancing efficacy | |
| CY1122855T1 (el) | Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου | |
| Braga et al. | A new age for iron: antitumoral ferrocenes | |
| Zamora et al. | Dual antitumor and antiangiogenic activity of organoplatinum (II) complexes | |
| Manic et al. | Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair | |
| Raza et al. | Monofunctional BODIPY-appended imidazoplatin for cellular imaging and mitochondria-targeted photocytotoxicity | |
| CY1114040T1 (el) | Συνδυαστικη θεραπεια του καρκινου περιλαμβανουσα αναστολεις των egfr/her2 | |
| Haririan et al. | Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines | |
| CY1114992T1 (el) | Μονοδιεσπαρμενες πεγκυλιωμενες συνθεσεις ναλοξολης | |
| Mehmood et al. | Review of cisplatin and oxaliplatin in current immunogenic and monoclonal antibodies perspective | |
| CY1112052T1 (el) | Γονιδια και πολυπεπτιδια που σχετιζονται προς τους καρκινους ανθρωπινων κολον | |
| Suntharalingam et al. | A dual-targeting, p53-independent, apoptosis-inducing platinum (II) anticancer complex,[Pt (BDIQQ)] Cl | |
| Panchangam et al. | Antitumor effects of Ir (III)-2 H-indazole complexes for triple negative breast cancer | |
| Alonso-de Castro et al. | Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis | |
| Shahsavari et al. | Fluorinated cycloplatinated (II) complexes bearing bisphosphine ligands as potent anticancer agents | |
| Clemente et al. | Platinacycles containing a primary amine platinum (II) compounds for treating cisplatin-resistant cancers by oxidant therapy | |
| Yin et al. | Multifunctional nanoparticles improve therapeutic effect for breast cancer by simultaneously antagonizing multiple mechanisms of multidrug resistance | |
| Wang et al. | Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin | |
| Jaros et al. | Self-assembly and multifaceted bioactivity of a silver (I) quinolinate coordination polymer | |
| Nano et al. | Rhodium complexes targeting DNA mismatches as a basis for new therapeutics in cancers deficient in mismatch repair | |
| Elie et al. | Auranofin-based analogues are effective against clear cell renal carcinoma in vivo and display No significant systemic toxicity | |
| Sahu et al. | LVVO-Ethyl Maltol-Based Metallodrugs (L2–= Tridentate ONO Ligands): Hydrophobicity, Hydrolytic Stability, and Cytotoxicity via ROS-Mediated Apoptosis |